Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

February 22, 2022

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 48 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being with us today as we go over Penumbra's results for the fourth quarter and the close of 2021. You can find the press release along with the financial tables — including the reconciliation from GAAP to non-GAAP — on the Investors section of our site, www.penumbrainc.com. On this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Actual outcomes may vary materially from what's stated or suggested by those forward-looking statements because of various risks and uncertainties, such as the ones described in our 10-K for the year ended December 31, 2021, which we expect to file with the SEC on February 22, 2022. So we urge you not to put undue reliance on these forward-looking statements, and we suggest you look at our periodic filings with the SEC — including that 10-K — for a fuller discussion of these factors and other risks that could impact our future results or the market price of our stock, such as, but not limited to, how COVID-19 affects our business, results of operations, and financial conditions. Penumbra has no obligation to update or revise these forward-looking statements because of new information, future events, developments, or anything else. Some financial measures on this call are presented on a non-GAAP basis. You'll find a reconciliation of GAAP to non-GAAP financial measures in the press release we posted; we expect the prepared remarks today will take about 20 minutes. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then go over our financial results for the fourth quarter and the full year; and Jason Mills, our Executive Vice President of Strategy, will cover our 2022 guidance; with that, I'll hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thank you, Jee. Good afternoon, everyone. We appreciate you being on Penumbra's call for the fourth quarter and year-end 2021. Fourth quarter total revenues came to $204 million. That's up 22.2% versus a year ago as reported, 23% in constant currency, and 7.3% higher sequentially compared with the third quarter. For all of 2021, annual revenues totaled $747.6 million, reflecting 33.4% growth relative to full year 2020; during the fourth quarter, we set revenue records in both Neuro and Vascular. We also began advancing toward our objective of creating a safe and secure health care platform that uses immersive computing to assist a substantial number of patients. Early in this first quarter of 2022, we dealt with the same macro difficulties every company in our space faces, among them serious staffing problems, especially at hospitals, supply limitations, growing inflation and additional COVID-related hurdles. Even so, our team has never been stronger and can handle the vital work needed to serve the millions of patients found in the 6 sizable under penetrated markets we address. Over the past 2 years of the pandemic, the Penumbra team brought a number of new paradigm-changing products to our physician customers, and we keep investing heavily in new innovation across each of these markets and in production to keep our supply chain as steady as we can; these investments are important to our business's long-term growth and profitability. We're also enthusiastic about several significant new products we plan to deliver to our customers in Neuro, Vascular and Immersive Healthcare later this year. Now let me take a few minutes to talk about how our team executed in the fourth quarter. Starting with Vascular. We posted global Vascular growth of 30.4% year-over-year, reaching $113.6 million in the fourth quarter, with solid results from both our thrombectomy and embolization franchises. Our vascular team has a tremendous amount of work ahead over the coming several years, since the growth opportunities in both franchises are considerable; this quarter, demand for our vascular embolization products picked up after the earlier COVID wave, rising 13% sequentially, which required a great deal of our team's focus. We also grew revenue both sequentially and year-over-year across all 4 vascular thrombectomy segments, ALI, DVT, coronary and PE, and we're well positioned in each of them going forward. Within only the last few years, we've introduced paradigm-changing technology into all 4 of these under penetrated markets. In them, more than 1 million patients can be helped annually. Almost 90% of those patients have not yet received treatment in single-session therapy; on the venous side. In DVT and PE, we witnessed a growing number of patients treated with our Lightning 12 technology during the second half of 2021. In particular, the fourth quarter saw the greatest number of new physician customers adopt Lightning 12. With this technology, we foresee an extended path of ongoing expansion, and we're also anticipating fresh innovation for venous patients that should arrive in late 2021. In a similar vein, our leadership in ALI keeps growing thanks to Lightning 7, which has seen strong uptake since it became available during Q2. Lightning 7 transformed how ALI is treated, and later this year we intend to enhance that approach too, using extra products that extend our patented computer-aided innovation. Regarding coronary thrombectomy, in November at the TCT conference we shared encouraging clinical results from the CHEETAH study, and those findings boosted recognition of what CAT RX can do for patients whose coronary lesions carry a heavy thrombus burden; our coronary business generated rising revenue during Q4, and we think this market's growth is still at an early point. The favorable patterns driving our robust expansion in both vascular thrombectomy and embolization reflect our distinctive products, a powerful commercial organization, and a dedication to clinical matters. Over the last 4 quarters, our top-tier vascular group brought in a greater number of new thrombectomy clients than during any comparable period in company history, and Q4 set a record for newly added customers. Moreover, moving forward, the group is engaging additional physicians inside our current accounts to deliver our technology to them; this matters because those physicians cover all 3 specialties in the field: interventional cardiologists, interventional radiologists, and vascular surgeons, and plenty of them perform procedures across more than 1 area; our position is strong since we've made substantial investments during recent years to equip our commercial organization to address the requirements of physicians across all 3 specialties through ongoing innovation and clinical dedication, which includes fresh, pertinent clinical trials in DVT, ALI and PE. Now let me discuss our Neuro business. During Q4, we achieved the quickest sequential improvement in close to 3 years, leaving out the initial COVID quarter, as our Neuro business grew 6.8% versus Q3 of 2021 and sped up to 13.3% year-over-year growth, reaching $90.4 million, powered by our stroke franchise. Following the prior quarter's 17% sequential rise in our U.S. stroke business, momentum from the RED catheters kept generating 11% sequential growth during Q4. Unit volume for the RED catheter has already surpassed the high point reached by our earlier-generation product lineup in 2019, prior to the pandemic and recall. RED 72 has turned into our top-selling product for large vessel strokes, and RED 62 has gone beyond every expectation. Beyond RED 62's strong utilization and distal aspiration, the product is being taken up at a far greater pace than expected for large vessel occlusions as a primary treatment, largely due to its status as the best tracking catheter available; we think catheter tractability will grow even more crucial as the market moves toward a new paradigm down the road. Looking ahead to 2022 and past that, our RED portfolio matters a great deal for a couple of reasons. First, we believe RED will keep fueling robust expansion and share gains for the stroke business, and not only within the U.S. — we'll also be rolling these products out across Europe, Japan, and additional geographies. Second, RED lays the groundwork for Thunderbolt, the biggest stroke innovation we've brought forward so far. Our conviction has only grown regarding the choice to run a U.S. trial for Thunderbolt. That trial, we believe, will show Thunderbolt's deep-reaching advantages, potentially reshaping how stroke intervention is done by markedly improving how quickly and how completely clots are taken out. Neuro access and embolization are areas where we're strongly positioned too. Over 12 months since launching in the U.S., adoption of BMX96 keeps climbing, and further innovations to that access product are planned for later this year. In the same way, interest has picked back up in our broader neuro coil lineup, a distinctive and vital product family serving some of the toughest embolization cases. Now shifting to Immersive Healthcare. Considerable strides have been made in the effort required to create the first virtual reality platform for health care. Building that platform means our 2022 efforts center on 3 key areas: first, we're advancing substantially on the technical front of platform development, covering both hardware and software; second, discussions of real importance have started with several top-tier companies spanning over a dozen health care channels, where upwards of 50 million patients stand to gain; and finally, we're looking into dozens of alliances with outside firms that might in time turn into a substantial supply of relevant content for patients using our platform. Last, turning to the international side of the business. The fourth quarter brought meaningful gains, with revenue up 19% versus the prior year. Thanks to forthcoming rollouts of our RED catheters and Lightning technology across multiple international markets, together with ongoing growth of operations in China and Japan, we're set up well for robust expansion internationally down the road. At this point I'd like to hand the call to Maggie, who will walk through the quarter's financial results.

Maggie Yuen

executive
#3

Thanks, Adam. Good afternoon to all of you. On today's call, I'll cover how we performed financially in Q4 and across the whole of 2021. Revenue and gross margin figures I cite are presented on a GAAP basis, whereas operating expenses — R&D, SG&A, and operating income included — are reported on a non-GAAP basis, leaving out nonrecurring and onetime items. You can find a GAAP-to-non-GAAP reconciliation in the press release we posted. Turning to the fourth quarter, which closed on December 31, 2021: total revenues came to $204 million. That represents a 22.2% reported rise, or 23% in constant currency, versus the fourth quarter of 2020, and a 7.3% sequential gain from the third quarter of 2021. Sales geographically broke down as 70.8% U.S. and 29.2% international. Compared with the same period in 2020, U.S. growth was 23.7% and international growth was 18.8% on a reported basis. Now for revenue by franchise. Our Vascular business brought in $113.6 million during the fourth quarter of 2021 — up 30.4% reported and 31.1% in constant currency against the prior-year period. Versus the preceding quarter, Vascular revenue rose 7.7%, with gains in the U.S. and every international region across both peripheral embolization and thrombectomy products. Our Neuro business posted $90.4 million in the fourth quarter of 2021, a 13.3% reported increase, or 14.1% in constant currency, from the same period a year earlier, reflecting robust growth in U.S. neuro thrombectomy and international neuro access volume. Gross margin for the fourth quarter of 2021 came in at 61.5%, versus 56.5% in the fourth quarter of 2020 and 63.1% in the prior quarter. The fourth quarter of 2020 carried a negative 900 basis point impact tied to product returns. Gross margin in the fourth quarter of 2021 fell below the prior quarter's level because of inflation — including a labor rate adjustment and higher logistic costs — plus some product and regional mix impact. Our stepped-up investment during 2021 in fixed costs, labor capacity, and manufacturing capabilities let us work through labor shortages and supply chain disruptions. Going forward, although these investments and inflationary pressures will keep weighing on gross margin, we might find opportunities for margin expansion during the second half of the year. Let's move on to operating expenses. During the quarter, we recorded nonrecurring research and development milestones and onetime expenses tied to the Sixense acquisition, along with amortization of acquired intangible assets, totaling $42.6 million — inside the $35 million to $45 million range I gave on the previous call. Accordingly, the fourth quarter financial metrics that follow reflect non-GAAP results, excluding the impact of those nonrecurring and onetime expenses. In the fourth quarter of 2021, total operating expenses reached $123 million, or 16.3% of revenue, compared with $96.1 million, or 57.6% of revenue, in the same quarter a year ago. For the fourth quarter of 2021, our R&D spending came to $19.4 million, versus $19.5 million in the same period of 2020. SG&A in Q4 2021 totaled $103.5 million, up from $76.6 million in Q4 2020. This rise in operating expenses came from adding more employees, greater travel and in-person activity, and putting money into growth opportunities; operating income for the quarter was $2.5 million, whereas a year earlier we posted an operating loss of $1.7 million. Let me now go over our results for the whole year; across full year 2021, total revenue reached $747.6 million, an increase of 33.4% as reported and 32.6% in constant currency over full year 2020. By geography, sales for the year split 70.6% U.S. and 29.4% international. U.S. grew 31.9% and International grew 37.3% versus a year ago. Our Vascular business generated revenue of $408.9 million for full year 2021, up 52.7% reported and 52.3% in constant currency. Our Neuro business brought in revenue of $338.7 million for full year 2021, up 15.7% reported and 14.6% in constant currency. Gross margin for the year was 63.6% of revenue, against 60.3% of revenue for full year 2020. If we exclude the 2021 impact from the nonrecurring research and development milestones, onetime expenses tied to Sixense acquisitions and amortization of acquired intangibles assets of $42.6 million that I mentioned earlier, along with the 2020 nonrecurring expense related to development and product launch of Lightning 12 of $20.7 million that we covered last year, then nonoperating — non-GAAP operating income for the full year was $35 million, compared with a non-GAAP operating loss of $18.3 million for 2020. Moving to cash flow and balance sheet. Accounts receivable rose by $13.9 million and net inventories rose by $5.2 million versus third quarter 2021. Our working capital level matched volume trends. We closed the fourth quarter of 2021 with $254.9 million in cash and cash equivalents and marketable securities and no debt. And now I'd like to hand the call over to Jason to discuss our 2022 guidance.

Jason Mills

executive
#4

Thanks, Maggie, and good afternoon, everyone. For the full year 2022, we're putting forward revenue guidance of $860 million to $875 million, which would mean growth of 15% to 17% compared with full year 2021 revenue of $747.6 million. The near-term macroeconomic difficulties Adam mentioned in his comments played a role during the opening weeks of this quarter, as other businesses in our sector have also seen. Going forward, we anticipate rolling out significant new products that will benefit our Neuro and Vascular businesses later in the year. All told, we anticipate solid sequential revenue growth, and we also anticipate that our quarterly revenue growth relative to year-ago periods will speed up as 2022 progresses, beginning at the low end of the guidance growth range and finishing near the high end. Broadly speaking, in line with how we have approached guidance in the past, our 2022 revenue guidance reflects our present view of our markets, the timing of new product launches and other pertinent inputs. I'll now hand the call back to Adam for closing remarks.

Adam Elsesser

executive
#5

Thanks, Jason, Maggie, and Jee. I'd like to wrap up what we prepared to say today by leaving you with 2 main takeaways. Number one, Penumbra stands in one of the most powerful spots it has ever occupied; we hold 6 sizable markets that remain under penetrated, best-in-class technology, and additional innovation coming down the pipeline; we recognize, based on what we've lived through before, that the road in front of us is difficult and requires patience, yet the payoff for patients from unlocking these big new markets is extraordinarily compelling, and our people are dedicated to meeting these demands. Number two, I want to close by giving credit to the physicians who use our products, along with the nurses and technicians, the administrators, and every member of staff at their hospitals. Clearly, what they accomplished during the pandemic is remarkable; even so, we recognize that the last 1.5 months, with hospitals facing serious staffing shortages, has pushed even the toughest to their limits. All the exhaustion we feel about the pandemic hasn't made things any simpler. I want each of you to know that we look up to your commitment, your empathy, and naturally, simply your sheer effort. I'm grateful for everything you've given, and I'm hopeful that the months to come will allow a shift back toward a more normal routine. Thank you. And now, thanks for listening in on today's call, and we'd like to turn it over for questions. Operator, please go ahead.

Robbie Marcus

analyst
#6

Nice work on the quarter. Adam, you brought up new product launches for 2022. I stopped counting how many times you mentioned it, but it was a lot — across both stroke and vascular, or Neuro and Vascular. Could you share some detail on what these launches will mean, how big the impact might be, and narrow down when during the year we could begin seeing them?

Adam Elsesser

executive
#7

Sure, that's a great question. Let me — without revealing anything it's too early to reveal, for clear reasons, let me try to frame it. Regarding neuro, what we've discussed — we've clearly discussed Thunderbolt, and we'll run a trial; we've said additional items are on the way within the remainder of that portfolio. So I'd like that to be clear; we're eager about ongoing innovation in the other areas of our business, along with stroke; on the vascular front. It truly boils down to how we've consistently viewed our businesses, meaning we keep considering the markets we operate in and how to improve the products further and further and further. And we're quite enthusiastic about certain innovations on the horizon. We believe they'll make the procedures, especially in thrombectomy, simpler, quicker, more thorough. That's the aim — to advance this field until physicians can examine these patients with clot, whether arterial, DVT, PE, or even coronary, and simply say, "Let's just take it out." And avoid treating it as some larger dilemma involving trade-offs. So that's been our pursuit for many years; and these innovations align with it extremely, extremely well.

Robbie Marcus

analyst
#8

Great, and I've got one more quick question. Adam, you ran the CHEETAH study in coronary late last year. Your vascular business is expanding quite nicely. What kind of effect should coronary have, in our view? It would also help to know how large it was during the quarter and what to expect as we head into 2022.

Adam Elsesser

executive
#9

Sure. We haven't put an exact dollar figure on it, but the first and clearest place to begin is with doctors who continue to use manual aspiration, particularly in light of the CHEETAH data. That looks like the most evident initial opportunity, considering how strong those results were, and especially by comparison. These are individuals who already accept that aspiration is essential for those patients. Once that happens, we'll naturally progress to the following segment — people who might be open to aspiration yet have held back, but after reviewing the CHEETAH data now view it as just as persuasive as we and other customers do. Regarding the second half of your question: clearly, we only had part of a quarter during which the CHEETAH data was available, not the whole thing. Still, its effect is undeniable — when you compare where things stood at the start versus the finish, something did shift. Yet we anticipate that trend carrying on for the rest of the year.

Larry Biegelsen

analyst
#10

I have two questions — one about Thunderbolt, one about REAL. Adam, we've run quite a few checks on Thunderbolt, and physicians appear quite enthusiastic about the idea. So what I want to know is: what shifted that made you decide to run a study prior to approval? Any details you can share on how the trial is designed? How long do you expect the trial and the filing to take? It also wasn't clear from what you said earlier whether that was part of the 2022 launches. And I had a follow-up.

Adam Elsesser

executive
#11

Okay. Well, that's something like 6 questions. So let me attempt to address all of them, and with any luck, I'll capture the essence. So we have been collaborating with the FDA. Clearly, I'm not ready at this point to spell out the precise trial design or the exact timing; but as I've mentioned before, and I want to restate this very plainly, this is — right now we are genuinely in a strong spot in stroke. The RED series is performing very well, and it's clearly a foundational element of using Thunderbolt. And so being able to keep delivering that technology to our customers across this year, I believe, is a key piece of the strategy. And then once the trial concludes, and again, I'll — the moment I'm able, I'll give you a more direct estimate regarding the timing; we'll put that on the table too. But even without it, and again, I'm tremendously excited about what our team has accomplished with that product. We have a great deal of really strong runway with the RED series, and the response keeps being quite remarkable. So I think we're — as I think has been pretty clearly hinted at, in a really, really strong position with our stroke franchise. Once you put the Thunderbolt on top of that, which isn't truly part of this year's expectations, it simply makes it even better; and you mentioned you had a follow-up.

Larry Biegelsen

analyst
#12

All right, so I want to make sure I've got this straight — Thunderbolt isn't part of what's coming out in 2022? Did I hear you correctly on that?

Adam Elsesser

executive
#13

Correct.

Larry Biegelsen

analyst
#14

All right. And moving on to REAL, Adam, is there any data you're able to provide regarding how things are going? I mean, up to this point, nothing has been disclosed about placements or anything along those lines. And what does the 2022 guidance factor in for REAL?

Adam Elsesser

executive
#15

Yeah. So REAL isn't something we're treating as a major revenue driver in 2022. That simply isn't how we're approaching that business. Over the coming year or so, what we're concentrating on is developing the platform itself, then doing the work of holding discussions with people in the channel who'd be deploying the REAL system for their patients, along with the third-party developers we're looking to have on the platform; so we'll make our best effort at that. And really, our aim is to do this during the second half of the year, beginning to offer whatever updates we can regarding how those discussions are progressing, with both the product's users and the third-party developers. And that genuinely is the finest means of gauging whether we're doing this the way we'd expected to or not; so once more, placing less emphasis on near-term revenue and more on treating this year, as I believe we've mentioned a few times, as a foundation for constructing this, truly, the first platform of its kind in immersive healthcare.

Bill Plovanic

analyst
#16

I have two things to ask. First, regarding guidance — when we consider Q1 and how much Omicron is affecting so many people, what's the right way to frame it? Should we view this as a big hit to January, meaning the quarter comes in roughly flat, either slightly up or slightly down? That's really my first question: how ought we to be thinking about Q1?

Adam Elsesser

executive
#17

Sure. I'll offer a brief — a somewhat broader perspective, and Jason, could you provide more detail on the latter portion of the question. We flagged it. As you're aware, I believe our company has managed the pandemic quite well across the past 2 years. And it's undeniable that this January wave, especially during the early part of January, the staffing challenges in particular, looked quite different. We've mentioned that previously, and it held true. There simply weren't workers available to operate at the levels required; that said, we — that area is now settled, and business remains very robust. But I'll have Jason speak to the quarter's particulars as thoroughly as we're able.

Jason Mills

executive
#18

Absolutely, Bill. Appreciate you asking. We just wrapped an exceptionally robust fourth quarter — a record-breaking one. Were it not for that standout, my expectation is that Q1 would likewise have set a record; therefore, we anticipate that going from the first quarter to the fourth, we'll witness sequential improvement along with year-over-year growth that speeds up in Q1. Considering what Adam mentioned regarding those initial weeks, our expectation is for the quarter and Q1 to decline on a sequential basis, followed by acceleration after that.

Bill Plovanic

analyst
#19

Great. And then a broader-picture question. I mean, Vascular has performed really strongly for you; we've noticed plenty of other companies beginning to look at this vertical, whether through buying others or launching new products. Philosophically speaking, how are you thinking about that going forward? Because it's nearly as if we're moving from a market with 2 or 3 players to suddenly becoming quite crowded across the coming 12 to 24 months.

Adam Elsesser

executive
#20

Yes; so to begin with, I'll mention the most obvious point, though it's important to state, I'm genuinely quite glad to watch a growing number of people putting faith in this area, caring about it and wanting to contribute, really, to a tremendous number of patients who require better technology and better treatment than what they've been receiving. So the validation that arrives when other companies enter this area, I believe, is truly significant. And I believe it will assist in accelerating the adoption of single-session therapy. So that matters. When it comes to our capacity to remain ahead and keep innovating and "compete", we've been doing this for some time. As you're aware, we've been doing it in stroke for a great many years. And considering where we stand, we're beginning from a completely different position with Lightning than we did previously in stroke; and we believe we can go even beyond that, as I hinted at, both during my prepared remarks and in the question. So I believe we're in a truly strong position. We're familiar with the technologies that exist out there. We feel good about where we stand. And I believe we, as an organization, will remain in a truly strong place. That said, once again, it's wonderful to see the attention being paid to these patients; and I believe that can only benefit us.

Brandon Vazquez

analyst
#21

Brandon here, filling in for Margaret. First thing I'd like to dig into is just the guidance. In 2021, you guys really beat the initial outlook you provided. I understand COVID may have restricted how much visibility you had; still, it appears that a year ago you gave somewhat cautious guidance and then surpassed it. And then, Adam, throughout the prepared remarks you kept using the term accelerate. So looking ahead to the coming year, I'm just wondering how you approached putting together the '22 revenue guidance, perhaps relative to your approach in '21, and what sort of potential upside that might imply as the year unfolds.

Adam Elsesser

executive
#22

Yes. Well, let me begin by sort of restating our philosophy on guidance. Our aim is to give guidance in the most accurate form we can. So we consider everything known to us nearly a year before it ends, and I believe we do a fairly solid job of planning and working out how matters will unfold, new products and all that included. That was our approach to guidance at the start of 2021, and it's our approach right now. Naturally, we were lucky in 2021, and we did beat it. It would be too soon to sit here today and look back and talk about that. But I believe the very same metrics we've relied on previously are in play. And Jason, would you like to chime in?

Jason Mills

executive
#23

Yeah — Brandon, I appreciate that question. Let me give you a bit of background here. Clearly, in 2020, COVID hit everyone's revenue, correct? Then 2021 was somewhat better, and in dollar terms, the revenue gain during 2021 exceeded $100 million by a wide margin. Even with such a strong 2021, at the bottom end of our guidance, we still anticipate more than $100 million in additional dollar revenue. And like we've discussed, we're excited about the innovation coming in both the Neuro and Vascular businesses, plus what we expect from Immersive Healthcare — which, to some degree, we haven't factored into this guidance, Thunderbolt included, as Adam said in response to an earlier question. So we feel very good about the state of the business and the guidance itself. That said, as Adam noted, it does incorporate the contribution we expect from those products we anticipate having across the year.

Brandon Vazquez

analyst
#24

Alright. So we touched briefly on upcoming launches of products overseas. Could you give us a better sense of which of your newest offerings, such as the RED and Lightning catheters, have already gone international? And for those that haven't, what nations could be added over the course of this year? What's the timeline we should be looking at? Also, please remind us where you operate internationally — selling direct, I believe — and where these devices are likely to have the greatest effect over the next, say, 12 months?

Adam Elsesser

executive
#25

Sure. Let's begin with the RED series, then shift to Lightning; so RED right now, aside from a handful of tiny nations, is essentially U.S.-based. As everyone knows, the 2 big markets outside the U.S. are Europe and Japan. I did say earlier that this is positioned for international expansion down the road and possibly in the latter portion of this year. As for Lightning, once more, apart from certain smaller nations, it's mainly in the U.S. at present. It's going to reach Europe ahead of the RED series. That's something we're thrilled about. There's a bit of maneuvering regarding reimbursement in certain of those nations. And Japan doesn't have it yet; still, we're eager to ultimately introduce it there too.

Joanne Wuensch

analyst
#26

Anthony here, filling in for Joanne. Just one fast question. Regarding the Thunderbolt milestone, could you share a bit more about what it involved? Or what those milestones consisted of?

Adam Elsesser

executive
#27

Sure. So it's — an arrangement existed with the individual who was instrumental in inventing and developing that product, under which, upon reaching a particular milestone in our work with the FDA, this payment would be made. That is the final payment — or the sole payment that exists. Once again, quite comparable to what took place with Lightning 2 years back. I believe if you look back, and you're able to check, I can't recall which quarter exactly, but we did something extremely similar. So it's along those lines.

David Rescott

analyst
#28

Nice work closing out the year so strongly. Let me start with the 2022 full-year outlook, if I may. How are you thinking about growth in each of the different segments? I recall that a recall affected neuro thrombectomy back in early 2021. That makes the year-over-year comparisons easier in neuro thrombectomy, and that segment probably had structural tailwinds that will carry into 2022. So with all of that in mind, how does each segment factor into the total growth guidance you gave for 2023? And should we be thinking about whether any particular segment shows particular strength or acceleration?

Adam Elsesser

executive
#29

Yeah, thanks for asking that. The way we look at our company — and I think how we talk about it shows this — is that we've got six big markets where penetration is still low, and five of those are in interventional, which will fuel our growth. This year, clearly, Immersive Healthcare is mostly an investment aimed at future growth. With luck, a few years from now, we'll be spending a lot of time discussing how that's powering growth. But near term, we're focused on those five interventional areas with low penetration. The sixth one is the embolization business in peripheral, which keeps expanding — it's just not really under penetrated. We simply keep performing well and gaining share. Every single one of those is important for this business to win, and I trust that came across clearly. We're putting money into each of them, and right now we've got, in every one, what you'd call top-tier tech — take stroke, or coronary alongside cataracts and the CHEETAH data, clearly, plus PE, DVT, and the arterial space. So honestly it's not — no single one of them is the one we're focused on. Those things could shift a bit from one quarter to the next, depending on how particular discussions with hospital staff and sales representatives unfold. Even so, each of them will fuel our expansion throughout this year and beyond, and ideally we'll layer the additional big opportunity in Immersive Healthcare on top. To put it simply without repeating myself too much, every piece contributes to what we've achieved. Jason, would you like to chime in?

Jason Mills

executive
#30

Yeah. The one point I would make, David, is that our position is quite solid across both the Neuro and Vascular segments. So out of those 5 interventional markets Adam mentioned, 4 sit within the Vascular business. Stroke, meanwhile, falls under Neuro. Each one is set to drive meaningful growth for us in 2022 and past 2022 as well. Still, it's worth keeping in mind that for 2022, just 4 of them come from Vascular and a single one comes from Neuro.

David Rescott

analyst
#31

Okay, that's useful. Adam, you said the RED series catheters have surpassed the peak sales from 2019 for the earlier catheter line. What do you figure was the main thing driving that? And then, thinking about it in terms of market share against — sorry, market growth against winning back share overall — how should we look at those when we consider how strong the RED series catheter has just been since it launched?

Adam Elsesser

executive
#32

Yeah. That's a wonderful question. So for us in 2021, I'd say a great deal of that expansion came through share. The market grew somewhat, we believe. But once more, like I've said before, so much of that effort has not yet truly come back. Everybody is prepared, everybody wants to — and the repeated surges last year sort of prevented folks from getting done some of the effort required. So if we get a bit of luck, we'll witness that shift in 2022. And I know when I speak with customers, there's plenty of enthusiasm; they're eager to see it expand; they're eager to see more patients treated. But many of our gains came by way of share in 2021. And I believe that will hold true moving forward too. I think there's additional share still to capture. Why — the first portion of the question is why or what brought that about. These are simply remarkable tools. The RED series ranks among the finest work we've ever produced. I'm tremendously proud of our R&D team and the innovation they delivered to it, particularly considering the conditions after 2020. Could not be more proud, and that is a hugely significant product. Once again, it matters not just today on its own, but it serves as a foundation for what's ahead, since it's among the things that would be used alongside Thunderbolt afterward, throughout the study and following the study.

Jee Hamlyn-Harris

executive
#33

Thanks, operator. Our management team and I want to express our appreciation once more for everyone being here today and for the attention you're giving Penumbra; we're eager to bring you up to speed on our Q1 call.

Operator

operator
#34

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.